Creating A Blueprint
For Inclusive Cancer Research
Smiling photo of Zafar Hakim, M.D., Vice President & Global Head of Portfolio Strategy Product Development, Genentech

We collectively worked alongside the U.S. Food and Drug Administration (FDA), the American Association for Cancer Research (AACR), and other industry leaders to publish insights and best practices, related to diversity and inclusion in cancer drug development, and empowering the industry's commitment to these ideals.

By implementing these best practices, clinical study sponsors can enhance representation and access to innovative cancer therapies for all patients. We aspire to ensure that every patient, regardless of their background, has an equal opportunity to participate in and benefit from cutting-edge research and development.

Clinical studies that lack diverse patient cohorts often have limited generalizability to the broader population we serve. By promoting inclusivity and accessibility, we aim to eliminate disparities in clinical research and ensure that the findings are applicable to a wider range of patients.
Our people data
As part of our commitment to Diversity & Inclusion, we are sharing enterprise-wide data related to our gender representation, race/ethnicity representation, and pay practices.
Answer The Call
We are looking for transformative visionaries like you to improve lives, patient care, and health equity. Your career is at Genentech.
Join Us
Genentech Logo
Genentech Logo
© 2023 Genentech USA, Inc. All rights reserved. This site is intended for US residents only.